Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory) after receiving CD19-directed chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy is a form of immunotherapy where the immune system cell, T-cell, is changed to attack cancer cells. Glofitamab is a bispecific antibody that can bind to two different antigens at the same time. Glofitamab binds to CD3, a protein found on T cells (a type of white blood cell), and CD20 a protein found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving glofitamab and obinutuzumab may be safe, tolerable, and/or effective in treating patients with relapsed or refractory mantle cell lymphoma after receiving CD19-directed CAR T-cell therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony chłoniak z komórek płaszcza, który powrócił lub nie zareagował na poprzednie leczenie.
- •Wcześniejsze leczenie terapią CAR-T ukierunkowaną na CD19 i nieskuteczność lub nietolerancja leczenia BTK.
- •Widoczna w badaniach obrazowych zmiana nowotworowa o określonych wymiarach.
- •Osoby powyżej 18. roku życia.
- •Ogólny stan zdrowia pozwalający na udział w badaniu (oceniany wg skali ECOG ≤ 2).
✗ Disqualifies
- •Dzieci poniżej 18. roku życia (ze względu na brak danych dotyczących bezpieczeństwa).
- •Pacjenci, u których wyniki badań krwi nie spełniają określonych norm (np. liczba białych krwinek, płytek krwi, funkcje wątroby i nerek).
- •Pacjenci z aktywnym zakażeniem wirusem zapalenia wątroby typu B lub niespełniający określonych warunków dotyczących leczenia HIV.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (9)
City of Hope Comprehensive Cancer Center
Duarte, United States
Emory University Hospital Midtown
Atlanta, United States
Emory University Hospital/Winship Cancer Institute
Atlanta, United States
Emory Saint Joseph's Hospital
Atlanta, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, United States
Case Western Reserve University
Cleveland, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, United States
Vanderbilt University/Ingram Cancer Center
Nashville, United States
Trial contact
Site Public Contact
Victor M. Orellana-Noia
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jonathon B. Cohen
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Cole H. Sterling
PRINCIPAL_INVESTIGATOR
Site Public Contact
Changchun Deng
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kami J. Maddocks
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jing-Zhou Hou
PRINCIPAL_INVESTIGATOR
Site Public Contact
Shakthi Bhaskar
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.